Stayble Therapeutics
0.27 SEK
-1.44 %
Less than 1K followers
STABL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-1.44 %
+95.71 %
+43.46 %
+21.78 %
+18.10 %
-41.14 %
-80.22 %
-96.21 %
-96.34 %
Stayble Therapeutics operates in the pharmaceutical industry. The company specializes in research and development of injection treatments for pain caused by herniated discs. The drug candidates are developed and based on a proprietary technological platform. Most operations are found in the Nordic market and the company has its headquarters in Gothenburg.
Read moreMarket cap
17.63M SEK
Turnover
790.75K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
21/5
2026
Interim report Q1'26
9/6
2026
General meeting '26
20/8
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
Kommuniké från extra bolagsstämma (tillika första kontrollstämma) i Stayble Therapeutics
Stayble Therapeutics AB har ingått en avsiktsförklaring med en internationell strategisk investerare för fortsatt finansiering av verksamheten
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools